Connection

TETSUO ASHIZAWA to RNA, Messenger

This is a "connection" page, showing publications TETSUO ASHIZAWA has written about RNA, Messenger.
Connection Strength

0.185
  1. Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trial. PLoS One. 2020; 15(4):e0231000.
    View in: PubMed
    Score: 0.108
  2. Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial. Lancet Neurol. 2023 03; 22(3):218-228.
    View in: PubMed
    Score: 0.033
  3. Decreased expression of myotonin-protein kinase messenger RNA and protein in adult form of myotonic dystrophy. Science. 1993 Apr 09; 260(5105):235-8.
    View in: PubMed
    Score: 0.017
  4. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum Mol Genet. 2006 Jul 01; 15(13):2138-45.
    View in: PubMed
    Score: 0.010
  5. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem. 2001 Mar 16; 276(11):7820-6.
    View in: PubMed
    Score: 0.007
  6. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet. 1998 Jan; 62(1):111-21.
    View in: PubMed
    Score: 0.006
  7. Effect of myotonic dystrophy trinucleotide repeat expansion on DMPK transcription and processing. Genomics. 1995 Jul 01; 28(1):1-14.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.